

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO |
|---|----------------|----------------------|-------------------------|-----------------|
| 09/731,349 | 12/06/2000 | Sreekant Nadkarni | 01-678 | 9200 |
| 7 | 590 07/16/2002 | | | |
| Pharmacia Corporation Patent Department Central, 1820 P.O. Box 5110 | | | EXAMINER | |
| | | | OH, SIMON J | |
| Chicago, IL 6 | 0680-5110 | | ART UNIT | PAPER NUMBER |
| • | | | 1615 | |
| 5 # | | | DATE MAILED: 07/16/2002 | 12_ |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | | 1 A | A self-seriffs | | | | |
|---|---|--|---|-----------------|--|--|--|
| • | | Application No. Applicant(s) | | | | | |
| • | Office Action Summany | 09/731,349 | NADKARNI ET AL. | NADKARNI ET AL. | | | |
| | Office Action Summary | Examiner | Art Unit | | | | |
| | | Simon J. Oh | 1615 | | | | |
| Period fo | The MAILING DATE of this communication app or Reply | ears on the cover sheet | with the correspondence addi | ress | | | |
| THE - Exte after - If the - If NO - Failu - Any | ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.15 SIX (6) MONTHS from the mailing date of this communication. In period for reply specified above is less than thirty (30) days, a reply or period for reply is specified above, the maximum statutory period or reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b). | 36(a). In no event, however, may y within the statutory minimum of t vill apply and will expire SIX (6) M , cause the application to become | a reply be timely filed hirty (30) days will be considered timely. ONTHS from the mailing date of this com ABANDONED (35 U.S.C. § 133). | nmunication. | | | |
| 1) | Responsive to communication(s) filed on | | | | | | |
| 2a) <u></u> □ | This action is FINAL . 2b)⊠ Th | is action is non-final. | | | | | |
| 3) 🗌 | Since this application is in condition for allowa closed in accordance with the practice under ion of Claims | | | merits is | | | |
| · _ | Claim(s) 1,3 and 5-18 is/are pending in the ap | plication | | | | | |
| • | 4a) Of the above claim(s) is/are withdraw | - | | | | | |
| | Claim(s) is/are allowed. | | | | | | |
| | 6)⊠ Claim(s) <u>1</u> is/are rejected. | | | | | | |
| | Claim(s) is/are objected to. | | | | | | |
| | Claim(s) are subject to restriction and/o | r election requirement. | | | | | |
| | on Papers | | | | | | |
| <i>'</i> _ | The specification is objected to by the Examine | | | | | | |
| 10)[| The drawing(s) filed on is/are: a)☐ accep | • | | | | | |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). | | | | | | | |
| 11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner. | | | | | | | |
| If approved, corrected drawings are required in reply to this Office action. 12) The oath or declaration is objected to by the Examiner. | | | | | | | |
| , | • | aniinei. | | | | | |
| | under 35 U.S.C. §§ 119 and 120 | n nriarity under 25 H.C.C | C 5 440(a) (d) ar (5) | | | | |
| 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: | | | | | | | |
| a) _l | | s have been received | • | | | | |
| | Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No. | | | | | | |
| | 3. Copies of the certified copies of the prior application from the International Bu | rity documents have bee reau (PCT Rule 17.2(a) | en received in this National S). | tage | | | |
| | See the attached detailed Office action for a list | • | | | | | |
| | Acknowledgment is made of a claim for domesti | • | | application). | | | |
| |) | * * | | | | | |
| Attachmen | | | | | | | |
| 2) 🔲 Notic | e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s) _ | 5) Notice | w Summary (PTO-413) Paper No(s) of Informal Patent Application (PTO- | | | | |

Application/Control Number: 09/731,349

Art Unit: 1615

DETAILED ACTION

Papers Received

1. Acknowledgment of receipt is made of the applicant's Information Disclosure Statements, received on January 5, 2002 and April 15, 2002. Acknowledgement of receipt is also made of the applicant's Amendment A, received on April 15, 2002.

Response to Arguments

- 2. The applicant's response has overcome the previous office action. The examiner withdraws the rejection under 35 U.S.C. 103(a) over Gao *et al.* in view of Lai *et al.* and Delgado, III *et al.*
- 3. Applicant's arguments with respect to claims 1, 3, and 5-18 have been considered but are most in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claim 1 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Application/Control Number: 09/731,349

Art Unit: 1615

The claim is confusing due to the language "to a fasting subject provides a time course of blood serum concentration of valdecoxib having a time to reach a concentration of 20 ng/ml not greater than 0.5 h after administration." The claim is directed to a composition *per se*, which would require the future delivery of the minimum of 20 mg. Clarification is requested as to the amount of valdecoxib in the particulate formulation. Do the applicants permit 20 mg/ml in the pharmaceutical composition?

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Simon J. Oh whose telephone number is (703) 305-3265. The examiner can normally be reached on M-F 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (703) 308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3014 for regular communications and (703) 305-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1234.

Simon J. Oh Patent Examiner AU 1615

sjo July 15, 2002

